🚀 VC round data is live in beta, check it out!
Immunic Valuation Multiples
Discover revenue and EBITDA valuation multiples for Immunic and similar public comparables like Ryvu Therapeutics, Agenus, Starpharma, Galectin Therapeutics and more.
Immunic Overview
About Immunic
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Founded
2003
HQ
Employees
77
Website
Sectors
Financials (LTM)
EV
$138M
Immunic Financials
Immunic reported last 12-month revenue of —.
In the same LTM period, Immunic generated — in gross profit and had net loss of ($101M).
Revenue (LTM)
Immunic P&L
In the most recent fiscal year, Immunic reported revenue of — and EBITDA of ($103M).
Immunic expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($103M) | XXX | XXX | XXX |
| Net Profit | ($101M) | XXX | ($97M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Immunic Stock Performance
Immunic has current market cap of $153M, and enterprise value of $138M.
Market Cap Evolution
Immunic's stock price is $1.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $138M | $153M | -9.3% | XXX | XXX | XXX | $-0.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImmunic Valuation Multiples
Immunic trades at (1.3x) EV/EBITDA.
EV / Revenue (LTM)
Immunic Financial Valuation Multiples
As of April 11, 2026, Immunic has market cap of $153M and EV of $138M.
Equity research analysts estimate Immunic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immunic has a P/E ratio of (1.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV (current) | $138M | XXX | $138M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.3x) | XXX | (1.3x) | XXX | XXX | XXX |
| P/E | (1.5x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Immunic Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Immunic Margins & Growth Rates
Immunic's revenue in the last fiscal year grew by —.
Immunic's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
Immunic Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Immunic Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ryvu Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Agenus | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Galectin Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Spero Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immunic M&A Activity
Immunic acquired XXX companies to date.
Last acquisition by Immunic was on XXXXXXXX, XXXXX. Immunic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Immunic
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialImmunic Investment Activity
Immunic invested in XXX companies to date.
Immunic made its latest investment on XXXXXXXX, XXXXX. Immunic invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Immunic
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Immunic
| When was Immunic founded? | Immunic was founded in 2003. |
| Where is Immunic headquartered? | Immunic is headquartered in United States. |
| How many employees does Immunic have? | As of today, Immunic has over 77 employees. |
| Who is the CEO of Immunic? | Immunic's CEO is Daniel Vitt. |
| Is Immunic publicly listed? | Yes, Immunic is a public company listed on Nasdaq. |
| What is the stock symbol of Immunic? | Immunic trades under IMUX ticker. |
| When did Immunic go public? | Immunic went public in 2014. |
| Who are competitors of Immunic? | Immunic main competitors are Ryvu Therapeutics, Agenus, Starpharma, Galectin Therapeutics. |
| What is the current market cap of Immunic? | Immunic's current market cap is $153M. |
| Is Immunic profitable? | No, Immunic is not profitable. |
| What is the current net income of Immunic? | Immunic's last 12 months net income is ($101M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.